Brokerages Set CureVac N.V. (NASDAQ:CVAC) Target Price at $6.83

Shares of CureVac N.V. (NASDAQ:CVAC) have received an average recommendation of “Hold” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $6.8333.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of CureVac in a research note on Tuesday, December 16th.

Institutional Investors Weigh In On CureVac

A number of hedge funds and other institutional investors have recently bought and sold shares of CVAC. Caitong International Asset Management Co. Ltd grew its position in shares of CureVac by 354.8% in the second quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company’s stock valued at $30,000 after purchasing an additional 4,375 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of CureVac in the second quarter worth $35,000. Integrated Wealth Concepts LLC raised its holdings in shares of CureVac by 25.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock valued at $42,000 after acquiring an additional 3,000 shares in the last quarter. Kathmere Capital Management LLC purchased a new stake in CureVac in the second quarter valued at approximately $60,000. Finally, L2 Asset Management LLC purchased a new stake in shares of CureVac during the 2nd quarter valued at $70,000. Institutional investors own 17.26% of the company’s stock.

CureVac Stock Down 0.2%

Shares of NASDAQ:CVAC opened at $4.66 on Friday. CureVac has a 1 year low of $4.00 and a 1 year high of $4.68. The company has a market capitalization of $1.05 billion, a PE ratio of 6.47 and a beta of 1.77. The business has a fifty day moving average price of $4.90 and a two-hundred day moving average price of $5.22. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.70 and a quick ratio of 3.69.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings results on Monday, November 24th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.07. The company had revenue of $63.53 million during the quarter, compared to analyst estimates of $21.40 million. CureVac had a net margin of 199.92% and a negative return on equity of 23.03%. Analysts forecast that CureVac will post 0.72 earnings per share for the current year.

About CureVac

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.